Australia-wide dispatch

Quantified
Peptides
PT-141 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

PT-141

Bremelanotide. Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About PT-141

Bremelanotide

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II via removal of the C-terminal amide group and cyclisation. It acts as a melanocortin receptor agonist with selectivity for MC3R and MC4R in the central nervous system, with reduced activity at the peripheral MC1R receptor responsible for melanogenesis.

Research has investigated PT-141 in melanocortin system signalling studies, hypothalamic neuropeptide pathway characterisation, and cyclic peptide pharmacology. It represents an important research tool for understanding central melanocortin circuit biology.

Type
Synthetic cyclic heptapeptide · MC3R/MC4R agonist
Research Areas
Melanocortin signalling, hypothalamic pathways, CNS research
Target Receptors
MC3R, MC4R (CNS)
Molecular Weight
1025.2 g/mol
Developer
Palatin Technologies
Primary Research
Melanocortin signalling, CNS pathways
Half-life
~2.7 hours (research models)
Research Origin
Derived from Melanotan II
  1. 01MC3R / MC4R Receptor AgonismPT-141 targets melanocortin receptors MC3R and MC4R in the central nervous system — differentiating it from Melanotan II which also activates the peripheral MC1R. Research examines its receptor binding kinetics and downstream CNS signalling effects.
  2. 02Hypothalamic Pathway StudiesLaboratory research has investigated PT-141's interaction with hypothalamic melanocortin circuits. Studies explore how MC4R activation in the hypothalamus modulates downstream neuropeptide signalling cascades.
  3. 03Cyclic Peptide Structure ResearchAs a cyclic heptapeptide, PT-141 offers structural stability advantages over linear analogues. Research has examined its structure-activity relationships and metabolic stability compared to its parent compound Melanotan II.

References

  1. 1Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
  2. 2Diamond LE et al. PT-141 clinical study overview. J Sex Med. 2004;1(3):268-275.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=PT-141+bremelanotide
  4. 4ClinicalTrials.gov: NCT studies on Bremelanotide

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range
HCG 10,000 IU — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

HCG

$100